Literature DB >> 7843954

Paroxetine in the treatment of chronic daily headache.

C A Foster, J Bafaloukos.   

Abstract

Forty-eight patients with chronic daily headache, unresponsive to several combinations of pharmacological treatments, were selected for an open-label study using paroxetine. Patients were given 10 mg to 50 mg of paroxetine for a period of 3 to 9 months. Ninety-two percent of the patients improved significantly, based on the patients' percent of the reduction in number of headache days per month. The common side effects were fatigue, insomnia, and urogenital disturbances. The possible mechanism of action of paroxetine in the treatment of chronic daily headache is discussed. Paroxetine appears to be effective in the treatment of chronic daily headache; however, double blind studies are needed to confirm these preliminary findings.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7843954     DOI: 10.1111/j.1526-4610.1994.hed3410587.x

Source DB:  PubMed          Journal:  Headache        ISSN: 0017-8748            Impact factor:   5.887


  10 in total

Review 1.  Paroxetine. An update of its pharmacology and therapeutic use in depression and a review of its use in other disorders.

Authors:  N S Gunasekara; S Noble; P Benfield
Journal:  Drugs       Date:  1998-01       Impact factor: 9.546

Review 2.  Psychiatric comorbidity of chronic daily headache: impact, treatment, outcome, and future studies.

Authors:  Shuu-Jiun Wang; Kai-Dih Juang
Journal:  Curr Pain Headache Rep       Date:  2002-12

Review 3.  Current Treatment Options: Headache Related to Menopause-Diagnosis and Management.

Authors:  Clinton G Lauritsen; Abigail L Chua; Stephanie J Nahas
Journal:  Curr Treat Options Neurol       Date:  2018-03-06       Impact factor: 3.598

4.  Treating chronic tension-type headache not responding to amitriptyline hydrochloride with paroxetine hydrochloride: a pilot evaluation.

Authors:  Kenneth A Holroyd; Jennifer S Labus; Francis J O'Donnell; Gary E Cordingley
Journal:  Headache       Date:  2003-10       Impact factor: 5.887

Review 5.  Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of tension-type headache in adults.

Authors:  Rita Banzi; Cristina Cusi; Concetta Randazzo; Roberto Sterzi; Dario Tedesco; Lorenzo Moja
Journal:  Cochrane Database Syst Rev       Date:  2015-05-01

Review 6.  Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of migraine in adults.

Authors:  Rita Banzi; Cristina Cusi; Concetta Randazzo; Roberto Sterzi; Dario Tedesco; Lorenzo Moja
Journal:  Cochrane Database Syst Rev       Date:  2015-04-01

7.  Pain and psychiatry: a critical analysis and pharmacological review.

Authors:  Donatella Marazziti; Francesco Mungai; Laura Vivarelli; Silvio Presta; Bernardo Dell'Osso
Journal:  Clin Pract Epidemiol Ment Health       Date:  2006-11-06

8.  A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Duliang Soft Capsule in Patients with Chronic Daily Headache.

Authors:  Shengyuan Yu; Yueqing Hu; Qi Wan; Jiying Zhou; Xinfeng Liu; Xiangyang Qiao; Xiaosu Yang; Jiachun Feng; Kangning Chen; Xiaoping Pan; Qingwu Yang; Linsen Dou; Ming Liu; Yangmei Chen; Tingmin Yu; Juming Yu; Zhiwei Li; Xue Bai; Jingfeng Duan
Journal:  Evid Based Complement Alternat Med       Date:  2015-05-26       Impact factor: 2.629

9.  Paroxetine increases delta opioid responsiveness in sensory neurons.

Authors:  Allison Doyle Brackley; Nathaniel A Jeske
Journal:  eNeuro       Date:  2022-07-25

Review 10.  Treating Chronic Pain with SSRIs: What Do We Know?

Authors:  Elias Patetsos; Emilia Horjales-Araujo
Journal:  Pain Res Manag       Date:  2016-07-03       Impact factor: 3.037

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.